On the second day of EASD 2021, three key press releases were observed from Lilly, Altimmune, and Lifescan. Below FENIX provides insights and context for the respective announcements.
A series of cardiometabolic-related news items have been observed: the Novo Nordisk Foundation and the Broad Institute of MIT and Harvard announced the launch of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease; Lifescan and Welldoc announced a partnership to integrate Welldoc’s chronic condition platform into the OneTouch Solutions portal; Xeris announced it received stockholder approval for the previously announced proposed acquisition of Strongbridge Biopharma; and Oramed announced it has reached over 50% enrollment in the Ph2 trial evaluating its oral insulin (ORMD-0801) in T2DM patients with NASH. Below, FENIX provides highlights and insights for the respective news items.
Lifescan and Cecelia Health announced the expansion of a multi-year partnership to offer users a fully integrated live telehealth service with the OneTouch Reveal app. Recall, Lifescan and Cecelia Health initially entered into the partnership in October 2020 starting with text-based coaching. According to the press release, Lifescan and Cecelia Health will launch a new, live Certified Diabetes Care and Education Specialists (CDCES) telehealth service through the OneTouch Reveal app which will be fully integrated into OneTouch Solutions. Below, FENIX provides thoughts on Lifescan’s apparent new strategy to expand its business model beyond traditional PBM reimbursement to either remain competitive or become attractive as an acquisition target.